Table of Contents
Presented on August 2, 2024.
PepGen presents myotonic dystrophy program, including PGN-EDODM1 program and nonclinical data and an overview of the FREEDOM-DM1 trial. Click here to learn more about PepGen.
Find the latest updates to the PepGen trial, including trial site recruiting status, on ClinicalTrials.gov.
Presenters include:
- Jane Larkindale, DPhil, Vice President of Clinical Science, PepGen
- Alayna Tress, MPH, Director of Patient Advocacy, PepGen
- Johanna Hamel, MD, Assistant Professor of Neurology, Pathology & Laboratory, University of Rochester Medical Center
MDF Resources referenced in the Video:
- Toolkits & Publications
- MDF Support Groups
- Digital Academy
- Calendar of Events
- DM Drug Development Pipeline
- Myotonic Dystrophy Family Registry (MDFR)
- 2025 MDF Annual Conference
- Sign up for My Dispatch, our monthly e-newsletter
About Meet the Myotonic Dystrophy Drug Developers
Biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates!
